

Page 1, line 9, please delete the text under "Cross-Reference to Related Applications" and substitute

mp
ci
N--This application is the U.S. National Phase of international application PCT/US96/20757, filed December 19, 1996, which claims priority to U.S. Serial No. 08/766,350, filed December 13, 1996, which claims the priority benefit to provisional application serial nos. 60/035,345 (converted from U.S. Serial No. 08/591,965), filed January 29, 1996, and 60/031,306 (converted from U.S. Serial No. 08/575,762), filed December 20, 1995, all of which are incorporated by reference herein in their entirety.

Page 8, line 28, please delete "12303 Parklawn Drive, Rockville, MD, U.S.A. 20852" and insert --10801 University Boulevard, Manassas, VA 20110-2209--;

Page 8, line 32, after "number" (first instance), please insert --60/031,306--; and

Page 46, line 29, after "No.", please insert --60/031,306--.

In the claims

Please enter the following amendments.

Please cancel claim 13.

B2
sub
c2
6. (Amended) A[n isolated] polynucleotide comprising a sequence encoding a polypeptide [having immunological activity of monoclonal anti-idiotypic antibody 11D10] that is capable of eliciting an anti-HMFG immunological response in a mammal, wherein the polypeptide comprises [at least 5 contiguous amino acids of a variable region of 11D10] an immunoglobulin variable region containing the three light chain complementarity determining regions (CDRs) of antibody 11D10 or an immunoglobulin variable region containing the three heavy CDRs of antibody 11D10, wherein antibody 11D10 is produced by the hybridoma deposited under ATCC Accession No. HB-12020 or progeny thereof.